JP2015535850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535850A5 JP2015535850A5 JP2015535750A JP2015535750A JP2015535850A5 JP 2015535850 A5 JP2015535850 A5 JP 2015535850A5 JP 2015535750 A JP2015535750 A JP 2015535750A JP 2015535750 A JP2015535750 A JP 2015535750A JP 2015535850 A5 JP2015535850 A5 JP 2015535850A5
- Authority
- JP
- Japan
- Prior art keywords
- phenoxy
- composition
- subject
- disease
- imidazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 208000024827 Alzheimer disease Diseases 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 13
- KJNNWYBAOPXVJY-UHFFFAOYSA-N 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-n,n-diethylpropan-1-amine Chemical compound CCCCC1=NC(C=2C=CC(OCCCN(CC)CC)=CC=2)=CN1C(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 KJNNWYBAOPXVJY-UHFFFAOYSA-N 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 7
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 7
- 239000000047 product Substances 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 102100037907 High mobility group protein B1 Human genes 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 230000006866 deterioration Effects 0.000 claims 3
- 229960003135 donepezil hydrochloride Drugs 0.000 claims 3
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 3
- USUHXXKCHSBMOS-XPSHAMGMSA-N galanthamine hydrochloride Chemical compound Cl.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 USUHXXKCHSBMOS-XPSHAMGMSA-N 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 229960004323 rivastigmine tartrate Drugs 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 229960003565 tacrine hydrochloride Drugs 0.000 claims 3
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 claims 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 230000036252 glycation Effects 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 229960000967 memantine hydrochloride Drugs 0.000 claims 2
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims 2
- 230000002829 reductive effect Effects 0.000 claims 2
- -1 s100b Proteins 0.000 claims 2
- 238000004904 shortening Methods 0.000 claims 2
- 230000004620 sleep latency Effects 0.000 claims 2
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 claims 1
- 101710168537 High mobility group protein B1 Proteins 0.000 claims 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims 1
- 102100029812 Protein S100-A12 Human genes 0.000 claims 1
- 101710110949 Protein S100-A12 Proteins 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019096786A JP6894940B2 (ja) | 2012-10-05 | 2019-05-23 | 軽度および中等度アルツハイマー病の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710229P | 2012-10-05 | 2012-10-05 | |
| US61/710,229 | 2012-10-05 | ||
| PCT/US2013/062964 WO2014055588A1 (en) | 2012-10-05 | 2013-10-02 | Treatment of mild and moderate alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019096786A Division JP6894940B2 (ja) | 2012-10-05 | 2019-05-23 | 軽度および中等度アルツハイマー病の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535850A JP2015535850A (ja) | 2015-12-17 |
| JP2015535850A5 true JP2015535850A5 (enExample) | 2016-11-24 |
| JP6566868B2 JP6566868B2 (ja) | 2019-08-28 |
Family
ID=49354960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535750A Active JP6566868B2 (ja) | 2012-10-05 | 2013-10-02 | 軽度および中等度アルツハイマー病の処置 |
| JP2019096786A Active JP6894940B2 (ja) | 2012-10-05 | 2019-05-23 | 軽度および中等度アルツハイマー病の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019096786A Active JP6894940B2 (ja) | 2012-10-05 | 2019-05-23 | 軽度および中等度アルツハイマー病の処置 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2903606A1 (enExample) |
| JP (2) | JP6566868B2 (enExample) |
| KR (1) | KR20150064743A (enExample) |
| CN (2) | CN104703592A (enExample) |
| AU (2) | AU2013327450B2 (enExample) |
| BR (1) | BR112015007641A8 (enExample) |
| CA (1) | CA2886785C (enExample) |
| EA (1) | EA201590687A1 (enExample) |
| HK (1) | HK1207004A1 (enExample) |
| IL (1) | IL237730B (enExample) |
| IN (1) | IN2015DN03734A (enExample) |
| MX (1) | MX377733B (enExample) |
| NZ (2) | NZ739521A (enExample) |
| SG (2) | SG11201502210VA (enExample) |
| WO (1) | WO2014055588A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019190823A1 (en) * | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| EP3864008A1 (en) | 2018-10-10 | 2021-08-18 | vTv Therapeutics LLC | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
| WO2020086388A1 (en) * | 2018-10-22 | 2020-04-30 | Vtv Therapeutics Llc | Glucokinase activator compositions for the treatment of cognitive impairment |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| CN114031687B (zh) * | 2021-11-12 | 2022-06-07 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026811A1 (en) * | 2003-05-20 | 2005-02-03 | Mjalli Adnan M. M. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| DK1482931T3 (da) * | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
| EP1707203A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
| JP2010523559A (ja) * | 2007-04-05 | 2010-07-15 | トランス テック ファーマ，インコーポレイテッド | ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態 |
| CN101663280A (zh) * | 2007-04-05 | 2010-03-03 | 转化技术制药公司 | [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ |
| WO2008153957A1 (en) * | 2007-06-07 | 2008-12-18 | The Trustees Of Columbia University In The City Of New York | Uses of rage antagonists for treating obesity and related diseases |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| US8933040B2 (en) * | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
-
2013
- 2013-10-02 BR BR112015007641A patent/BR112015007641A8/pt active Search and Examination
- 2013-10-02 CA CA2886785A patent/CA2886785C/en active Active
- 2013-10-02 IN IN3734DEN2015 patent/IN2015DN03734A/en unknown
- 2013-10-02 EP EP13776676.2A patent/EP2903606A1/en not_active Withdrawn
- 2013-10-02 EA EA201590687A patent/EA201590687A1/ru unknown
- 2013-10-02 HK HK15107776.8A patent/HK1207004A1/xx unknown
- 2013-10-02 NZ NZ739521A patent/NZ739521A/en unknown
- 2013-10-02 SG SG11201502210VA patent/SG11201502210VA/en unknown
- 2013-10-02 CN CN201380051206.0A patent/CN104703592A/zh active Pending
- 2013-10-02 WO PCT/US2013/062964 patent/WO2014055588A1/en not_active Ceased
- 2013-10-02 AU AU2013327450A patent/AU2013327450B2/en active Active
- 2013-10-02 SG SG10201702648YA patent/SG10201702648YA/en unknown
- 2013-10-02 CN CN201910466681.3A patent/CN110292638A/zh active Pending
- 2013-10-02 NZ NZ705813A patent/NZ705813A/en unknown
- 2013-10-02 KR KR1020157011366A patent/KR20150064743A/ko not_active Ceased
- 2013-10-02 JP JP2015535750A patent/JP6566868B2/ja active Active
- 2013-10-02 MX MX2015003732A patent/MX377733B/es active IP Right Grant
-
2015
- 2015-03-12 IL IL237730A patent/IL237730B/en active IP Right Grant
-
2018
- 2018-05-16 AU AU2018203434A patent/AU2018203434A1/en not_active Abandoned
-
2019
- 2019-05-23 JP JP2019096786A patent/JP6894940B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220249515A1 (en) | Ganaxolone for use in treating genetic epileptic disorders | |
| JP2015535850A5 (enExample) | ||
| Wallace et al. | New insights into mechanisms of therapeutic effects of antimalarial agents in SLE | |
| JP5992049B2 (ja) | 置換されたキナゾリノンのための経口速放性製剤 | |
| JP2021514358A (ja) | アピリモドとグルタミン酸作動薬を用いた併用療法 | |
| US20130172414A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
| JP2021152008A (ja) | ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物 | |
| JP6894940B2 (ja) | 軽度および中等度アルツハイマー病の処置 | |
| CN105473144A (zh) | 用于加速斑块消退的组合物和治疗方法 | |
| Duggan et al. | Immune modulation to treat Alzheimer’s disease | |
| WO2015032966A1 (en) | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease | |
| Askarian et al. | A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients | |
| CN103948834B (zh) | 一种薏仁麸皮提取物及其制备方法和用途 | |
| KR20160118234A (ko) | 만성 신장병의 진행 억제 또는 개선제 | |
| Nourian et al. | Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of α1-adrenoceptor function | |
| JP2019530711A (ja) | アピリモド組成物およびそれをアルツハイマー病の処置に使用するための方法 | |
| CN105343024A (zh) | 一种阿托伐他汀钙片剂及其制备方法 | |
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| TW202333753A (zh) | 心腦血管藥物及其應用 | |
| CN109260217A (zh) | 3`-脱氧次黄嘌呤核苷在制备用于多种疾病药品、食品或保健品中的应用 | |
| CN113613653A (zh) | 治疗边缘型人格障碍的方法 | |
| US20240024332A1 (en) | Apilimod compositions and methods of use | |
| WO2025050793A1 (zh) | 用于预防、改善及/或治疗肌肉疾病或肌肉失调的组合 | |
| KR20250144469A (ko) | 헌팅턴병 및 이의 증상을 치료하기 위한 방법 및 조성물 | |
| Cramb et al. | UK consensus position on the management of homozygous familial hypercholesterolaemia and the introduction of new agents |